Quarterly report · Q2
4005.TEDINET S100PHEX
Period2022-04-01 → 2022-09-30
Filed2022-11-08
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 59
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.53T | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥754.4bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥2.77T | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.33T | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥686.2bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥60.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥5.7bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥144.3bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥85.9bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥126.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥13.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥251.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥146.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥90.1bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥81.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥11.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥162.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥88.9bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥53.2bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥73.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥12.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥186.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥107.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥68.9bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥4.68T | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥4.31T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.08T | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.79T | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.61T | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.89T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.70T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.55T | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.48T | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.38T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.22T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.08T | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥486.0bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥365.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥346.8bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥360.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥83.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥171.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥77.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥115.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥65.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥24.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥81.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥27.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥49.58 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥6.77 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥99.16 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥54.36 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥32.55 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥49.57 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥6.77 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 29.5% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.3% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.5% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 124
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥79.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-07-01 → 2022-09-30 | ¥47.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥37.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-07-01 → 2022-09-30 | ¥23.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥42.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥24.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥708m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥57.6bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥32.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥57.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥32.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥11.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥4.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥183.7bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥92.4bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥173.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥87.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥470.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥230.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥467.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥228.7bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥23.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥13.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥295.9bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥142.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥293.9bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥141.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥36.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥14.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥222.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥107.7bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥222.2bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥107.5bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥234m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥118m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥26.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥10.7bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥334.5bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥166.7bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥334.4bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥166.7bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥25.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥11.1bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.51T |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥739.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.49T |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥731.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥15.5bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥8.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥124.7bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥56.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥59.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-07-01 → 2021-09-30 | ¥31.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥30.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-07-01 → 2021-09-30 | ¥17.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥29.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥14.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥6.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-07-01 → 2021-09-30 | ¥4.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥41.3bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥20.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥41.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥20.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥10.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥5.4bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥154.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥77.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥148.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥74.1bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥12.6bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥5.9bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥402.1bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥201.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥399.5bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥200.0bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥42.0bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥212.8bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥107.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥209.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥106.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥955m |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥18.5bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥8.2bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥227.9bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥118.5bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥227.7bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥118.4bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥226m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥116m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥29.5bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥16.0bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥309.6bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥170.4bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥309.6bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥170.4bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥9m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥50.0bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥40.3bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥1.31T |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥674.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥1.29T |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥669.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥12.2bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥5.5bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥152.6bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥88.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 994
| Item | Context | Value | Unit |
|---|---|---|---|
| Business structure improvement expenses ope cf IFRS | Prior1YTDDuration | 3002000000 | JPY |
| Business structure improvement expenses ope cf IFRS | CurrentYTDDuration | 8438000000 | JPY |
| Change in fair value of contingent consideration ope cf IFRS | Prior1YTDDuration | 143000000 | JPY |
| Change in fair value of contingent consideration ope cf IFRS | CurrentYTDDuration | -1287000000 | JPY |
| Loss gain on sale of fixed assets ope cf IFRS | Prior1YTDDuration | -154000000 | JPY |
| Loss gain on sale of fixed assets ope cf IFRS | CurrentYTDDuration | -3511000000 | JPY |
| Decrease increase in trade receivables ope cf IFRS | Prior1YTDDuration | 2133000000 | JPY |
| Decrease increase in trade receivables ope cf IFRS | CurrentYTDDuration | 74690000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -71764000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -107651000000 | JPY |
| Increase decrease in trade payables ope cf IFRS | Prior1YTDDuration | 19150000000 | JPY |
| Increase decrease in trade payables ope cf IFRS | CurrentYTDDuration | 7427000000 | JPY |
| Increase decrease in unearned revenue ope cf IFRS | Prior1YTDDuration | 3140000000 | JPY |
| Increase decrease in unearned revenue ope cf IFRS | CurrentYTDDuration | -3523000000 | JPY |
| Increase decrease in provisions ope cf IFRS | Prior1YTDDuration | -4011000000 | JPY |
| Increase decrease in provisions ope cf IFRS | CurrentYTDDuration | 9299000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -45601000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -107324000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 107988000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 117633000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 14817000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 12253000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -7336000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -11623000000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YTDDuration | -36525000000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYTDDuration | -33084000000 | JPY |
| Business structure improvement expenses paid ope cf IFRS | Prior1YTDDuration | -1746000000 | JPY |
| Business structure improvement expenses paid ope cf IFRS | CurrentYTDDuration | -1663000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 77198000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 83516000000 | JPY |
| Decease increase of marketable securities inv cf IFRS | Prior1YTDDuration | -12973000000 | JPY |
| Decease increase of marketable securities inv cf IFRS | CurrentYTDDuration | -13504000000 | JPY |
| Purchase of non current assets inv cf IFRS | Prior1YTDDuration | -47774000000 | JPY |
| Purchase of non current assets inv cf IFRS | CurrentYTDDuration | -68914000000 | JPY |
| Proceeds from sales of non current assets inv cf IFRS | Prior1YTDDuration | 890000000 | JPY |
| Proceeds from sales of non current assets inv cf IFRS | CurrentYTDDuration | 4174000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -12455000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -3735000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | Prior1YTDDuration | 9068000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | CurrentYTDDuration | 41625000000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 844000000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 64331000000 | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -2750000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | -8421000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -65150000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | 15556000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | 27461000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | 20174000000 | JPY |
| Net increase decrease in commercial paper fin cf IFRS | Prior1YTDDuration | 27000000000 | JPY |
| Net increase decrease in commercial paper fin cf IFRS | CurrentYTDDuration | 88000000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |